Author presents a bullish UNCY thesis centered on likely FDA approval in 2026 and cash runway into 2027.
UNCY — LONG Unicycive resubmitted after a CRL with only one issue and is expected to receive either a Class 1 approval in February 2026 or a Class 2 PDUFA decision by end of June 2026. The company's $42M cash plus $25M from warrants upon approval provides runway into 2027. The author expects to profit as with a prior similar biotech MIST.
Now there is a chance we get a Class 1 Resubmission which would put approval in Feb2026, more likely we will get a Class 2 and the PDUFA date will be end of Jun2026.
This Reddit post, published January 07, 2026, features u/RunningRobert1980 discussing UNCY. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/RunningRobert1980 · Tickers: UNCY